- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05547932
The Effect of Rhomboid Intercostal Block and Serratus Anterior Plane Block on Postoperative Respiratory Functions (RIBSAB)
April 15, 2023 updated by: Başak Altıparmak, Muğla Sıtkı Koçman University
The Effect of Ultrasound-guided Rhomboid Intercostal Block and Serratus Anterior Plane Block on Postoperative Respiratory Functions and Analgesia After Breast Surgery
Rhomboid intercostal block is used to block lateral cutaneous branches of intercostal nerves between T3 and T9 dermatomes.
Serratus anterior plane block is used to block lateral cutaneous branches of intercostal nerves between T2 and T6, in addition, it is also known to block thoracodorsal nerve and long thoracic nerve.
Both of the blocks are usually performed for postoperative analgesia following breast surgery.
The primary hypothesis of the study is that FEV1 value of the patients who will receive modified radical mastectomy (MRM) and rhomboid intercostal plane (RIP) block combined with serratus anterior plane (SAP) will be higher than FEV1 value of the patients in the no-block group.
The secondary hypothesis is that RIP+SAP blocks will provide reduction in the pain scores and opioid consumption in the postoperative first 24 hours.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
The patients who are scheduled for MRM under general anesthesia, aged between 18-65 years and ASA scores I-II will be included in the study.
Respiratory functions (FEV₁, FVC, FEV₁/FVC, PEF, FEF25-75) of the patients will be measured by a hand-held spirometry device prior to the operation in the surgical ward.
The induction of anesthesia will be provided similarly in all patients, then patients will be intubated and randomly divided into two groups.
One group will receive RIP+SAP block using 40 milliliters of %0.25 bupivacaine and patients in the control group will receive no block procedures.
The standard analgesia will be provided by intraoperative intravenous (iv) infusion of dexketoprofen 50 mg and iv tramadol 1 mg/kg which will be administered in 15 minutes before end of the surgery.
Respiratory functions of the patients will be measured at the postoperative 2nd, 4th and 24th hours.
Pain intensity of the patients will be evaluated by Numerical Rating Scale (NRS) which is a scale ranges between 0 (no pain) and 10 (the worst pain that a person can stand).
NRS scores will be evaluated at the postoperative 15th, 30th minutes and 1st, 2nd, 6th, 12th and 24th hours, and opioid consumption will be recorded at the postoperative 24th hour.
Study Type
Interventional
Enrollment (Actual)
64
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Muğla, Turkey, 48000
- Muğla Sıtkı Koçman University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- ASA I-II patients
- Female
- Ages between 18-65
- Patients who will receive breast cancer surgery under general anesthesia
Exclusion Criteria:
- Known respiratory diseases
- Rhinitis and atopic dermatitis story
- New York Heart Association Class equal to higher than class 2
- Respiratory diseases story in the last two weeks
- Alchol or substance or chronic opioid consumption story
- Any pain killers intake in the last 24 hours prior to surgery
- Active smokers or ex-smokers
- Body mass index over 35 kg/m2
- İnfection at the injection sites
- Known allergy to local anesthetics
- Known psychiatric diseases
- Operations longer than 3 hours
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Block Group
After endotracheal intubation, patients will be positioned in lateral decubitus position.
A linear ultrasound probe will be placed at the edge of scapula at the level of T5-T6.
Under sterile conditions, the landmark points (rhomboid major muscle, 5th and 6th ribs, and intercostal muscles) will be observed and a block needle will be directed to the interfacial plane between rhomboid major muscle and intercostal muscle.
RIB will be performed by injecting 20 ml of bupivacaine 0.25%.
In the same position, the probe will be placed at the midaxillary line at the level of T3, and the landmark points (latissimus dorsi muscle and serratus muscle and intercostal muscles) will be observed.
Under sterile conditions, a SAP block will be performed by injecting 20 ml of Bupivacaine 0.25% into the plane between serratus muscle and intercostal muscle.
|
RIB block will be performed after endotracheal intubation, then a SAP block will be performed.
No other intervention will be performed to the patients.
|
|
No Intervention: Control Group
No block procedures will be performed in this group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Forced Expiratory Volume in 1 second (FEV1)
Time Frame: postoperative 2nd hour
|
FEV1 of the patients in the block group will be higher at the postoperative second hour than the patients in the control group
|
postoperative 2nd hour
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Postoperative pain
Time Frame: Postoperative second hour
|
The pain scores of the patients in the block group will be lower than the patients in the control group at the postoperative second hour.
|
Postoperative second hour
|
|
Postoperative opioid consumption
Time Frame: Postoperative 24th hour
|
The opioid consumption of the patients in the block group will be lower than the patients in the control group at the postoperative 24th hour.
|
Postoperative 24th hour
|
|
Forced Vital Capacity (FVC)
Time Frame: postoperative 2nd hour
|
FVC value of the patients in the block group will be higher at the postoperative second hour than the patients in the control group
|
postoperative 2nd hour
|
|
FEV1/FVC
Time Frame: postoperative 2nd hour
|
FEV1/FVC value of the patients in the block group will be higher at the postoperative second hour than the patients in the control group
|
postoperative 2nd hour
|
|
forced expiratory flow at 25-75% of forced vital capacity (FEF25-75)
Time Frame: postoperative 2nd hour
|
FEF25-75 values of the patients in the block group will be higher at the postoperative second hour than the patients in the control group
|
postoperative 2nd hour
|
|
Peak expiratory flow (PEF)
Time Frame: postoperative 2nd hour
|
PEF values of the patients in the block group will be higher at the postoperative second hour than the patients in the control group
|
postoperative 2nd hour
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 21, 2022
Primary Completion (Actual)
April 13, 2023
Study Completion (Actual)
April 14, 2023
Study Registration Dates
First Submitted
August 10, 2022
First Submitted That Met QC Criteria
September 18, 2022
First Posted (Actual)
September 21, 2022
Study Record Updates
Last Update Posted (Actual)
April 19, 2023
Last Update Submitted That Met QC Criteria
April 15, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MSK8/22
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
IPD will not be shared with anyone
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.